The Australian Autosomal Dominant Polycystic Kidney Disease Therapeutics market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Autosomal dominant polycystic kidney disease is the most common inherited kidney disease, characterized by the growth of a number of cysts in the kidney. Patients with autosomal dominant polycystic kidney disease generally begin to show symptoms at the age of 30-40 years and rarely in childhood. The most common symptoms of autosomal dominant polycystic kidney disease include pain in the back & sides and headache. Autosomal dominant polycystic kidney disease is diagnosed by kidney imaging using ultrasound, CT scans, or MRI imaging. Genetic testing is done to confirm the diagnosis. Symptomatic treatment for autosomal dominant polycystic kidney disease involves pain medications, removal of kidney cysts, controlling high blood pressure and acidosis, restricting progression of kidney failure, etc. Along with pharmacological treatment, diet control is recommended to slow down the progression of autosomal dominant polycystic kidney disease. Recently in 2018, Therapeutic Goods Administration (TGA) approved the first and only treatment Tolvaptan to retard the progression of autosomal dominant polycystic kidney disease.



Market Growth Drivers & Restraints

The Australian market for autosomal dominant polycystic kidney disease is primarily driven by improving diagnosis rates for autosomal dominant polycystic kidney disease and the penetration of symptomatic treatment. Pharmaceutical companies and research institutes are continuously putting efforts into research and development to address the unmet needs in autosomal dominant polycystic kidney disease treatment, which is expected to accelerate the growth of the market. However, underreported epidemiology of autosomal dominant polycystic kidney disease and lack of awareness towards the disease among the population is expected to restrict the growth of the autosomal dominant polycystic kidney disease treatment market.